2024
Hepatorenal Syndrome Type 1: Diagnosis and Treatment
Belcher J. Hepatorenal Syndrome Type 1: Diagnosis and Treatment. Advances In Kidney Disease And Health 2024, 31: 100-110. PMID: 38649214, DOI: 10.1053/j.akdh.2023.05.001.Peer-Reviewed Original ResearchConceptsAcute kidney injuryHepatorenal syndromeKidney injuryFunctional acute kidney injuryUrinary biomarkers of kidney injuryAssociated with significant morbidityFractional excretion of sodiumNeutrophil gelatinase-associated lipocalinDiagnostic criteriaBiomarkers of kidney injuryMultiple urinary biomarkersOptimal dosing strategiesExcretion of sodiumPoint-of-care ultrasoundAccurate differential diagnosisAnalog of vasopressinSets of diagnostic criteriaAdvanced cirrhosisAlbumin administrationSignificant morbidityVolume resuscitationTherapeutic optionsDosing strategiesFractional excretionDifferential diagnosis
2023
Good Enough? Terlipressin, Hepatorenal Syndrome, and the Usage of RRT
Belcher J. Good Enough? Terlipressin, Hepatorenal Syndrome, and the Usage of RRT. Kidney360 2023, 4: 1011-1013. PMID: 37651662, PMCID: PMC10484352, DOI: 10.34067/kid.0000000000000217.Peer-Reviewed Original ResearchIncidence and outcomes of acute kidney injury including hepatorenal syndrome in hospitalized patients with cirrhosis in the US
Patidar K, Belcher J, Regner K, St. Hillien S, Simonetto D, Asrani S, Neyra J, Sharma P, Velez J, Wadei H, Nadim M, Chung R, Seethapathy R, Parada X, Ouyang T, Ufere N, Robinson J, Diaz P, Wilechansky R, Przybyszewski E, Smith T, Ali A, Orman E, Schulz P, Siddiqui S, Shabbir R, Liu L, Cama-Olivares A, Flannery A, Baker M, Gunasekaran D, Aswine A, Issa R, Li J, Verma S, Chalmers D, Varghese V, Lam W, Mohamed M, Kovacic R, Gaddy A, Attieh R, Cortes P, Semnani S, Wang L, Khemichian S, Allegretti A, consortium F. Incidence and outcomes of acute kidney injury including hepatorenal syndrome in hospitalized patients with cirrhosis in the US. Journal Of Hepatology 2023, 79: 1408-1417. PMID: 37517455, PMCID: PMC10807505, DOI: 10.1016/j.jhep.2023.07.010.Peer-Reviewed Original ResearchConceptsEtiology of AKIHRS-AKISubdistribution hazard ratiosHepatorenal syndromePrerenal AKIKidney injuryHigh morbidityIncidence ratePractice patternsSimilar outcomesHigher AKI stageAcute kidney injuryRetrospective cohort studyAcute tubular necrosisConsecutive adult patientsEtiology of injuryAKI stageAKI definitionLiver transplantAdult patientsCohort studyHazard ratioSevere complicationsTubular necrosisComplete responseHepatorenal Syndrome Pathophysiology, Diagnosis, and Treatment
Belcher J. Hepatorenal Syndrome Pathophysiology, Diagnosis, and Treatment. Medical Clinics Of North America 2023, 107: 781-792. PMID: 37258014, DOI: 10.1016/j.mcna.2023.03.009.Peer-Reviewed Original ResearchConceptsAcute kidney injuryHepatorenal syndromeCombination of midodrineFirst-line standardPooling of bloodAnalog of vasopressinIntravenous albuminKidney injuryLiver transplantationVasoconstrictor agentsDefinitive treatmentPathophysiologic cascadeSplanchnic systemSyndrome pathophysiologyArterial volumeTreatmentTerlipressinCirrhosisMidodrineOctreotidePatientsTransplantationPathophysiologySyndromeInjuryRecent Advances in the Management of Hepatorenal Syndrome: A US Perspective
Patidar K, Piano S, Cullaro G, Belcher J, Allegretti A, Consortia H. Recent Advances in the Management of Hepatorenal Syndrome: A US Perspective. Clinical Gastroenterology And Hepatology 2023, 21: 897-901.e1. PMID: 36801201, PMCID: PMC10038893, DOI: 10.1016/j.cgh.2022.12.034.Peer-Reviewed Original ResearchResponsiveness to Vasoconstrictor Therapy in Hepatorenal Syndrome Type 1
Velez J, Karakala N, Tayebi K, Wickman T, Mohamed M, Kovacic R, Therapondos G, Kanduri S, Allegretti A, Belcher J, Regner K, Wentowski C. Responsiveness to Vasoconstrictor Therapy in Hepatorenal Syndrome Type 1. Kidney360 2023, 4: e448-e456. PMID: 36763632, PMCID: PMC10278824, DOI: 10.34067/kid.0000000000000068.Peer-Reviewed Original ResearchConceptsHepatorenal syndrome type 1Mean arterial pressureSyndrome type 1HRS-1Baseline SCrMAP riseType 1Serum creatinineArterial pressureKidney functionDay 14Baseline mean arterial pressureMean mean arterial pressureMedian mean arterial pressureEnd-stage liver diseaseMultivariate logistic regression analysisFavorable renal outcomeOptimal MAP targetsUse of norepinephrineLogistic regression analysisGreater reductionMedian sCrNorepinephrine useVasoconstrictor therapyRenal outcomes
2022
Towards a Better Crystal Ball: Urinary C-C Motif Chemokine Ligand 14 (CCL14) and Persistent Severe AKI
Belcher JM. Towards a Better Crystal Ball: Urinary C-C Motif Chemokine Ligand 14 (CCL14) and Persistent Severe AKI. Kidney360 2022, 3: 1124-1127. PMID: 35919534, PMCID: PMC9337887, DOI: 10.34067/kid.0002162022.Peer-Reviewed Original ResearchBile Acids Are Important Contributors to AKI Associated with Liver Disease: CON
Allegretti AS, Belcher JM. Bile Acids Are Important Contributors to AKI Associated with Liver Disease: CON. Kidney360 2022, 3: 21-24. PMID: 35378020, PMCID: PMC8967622, DOI: 10.34067/kid.0006512020.Peer-Reviewed Original Research
2021
Terlipressin and the Treatment of Hepatorenal Syndrome: How the CONFIRM Trial Moves the Story Forward
Belcher JM, Parada XV, Simonetto DA, Juncos LA, Karakala N, Wadei HM, Sharma P, Regner KR, Nadim MK, Garcia-Tsao G, Velez JCQ, Parikh SM, Chung RT, Allegretti AS, Investigators H. Terlipressin and the Treatment of Hepatorenal Syndrome: How the CONFIRM Trial Moves the Story Forward. American Journal Of Kidney Diseases 2021, 79: 737-745. PMID: 34606933, DOI: 10.1053/j.ajkd.2021.08.016.Peer-Reviewed Original ResearchConceptsAcute kidney injuryHepatorenal syndromeRespiratory adverse eventsPrimary end pointFirst-line therapyMean arterial pressureSympathetic nervous systemSynthetic vasopressin analogueAdvanced cirrhosisHRS reversalAldosterone systemKidney injuryLack of evidenceAdverse eventsMortality benefitPortal pressureArterial pressureFulminant formSplanchnic systemSignificant morbidityRenal vasculatureVasodilatory substancesApparent increased rateTerlipressinCONFIRM trialsUrinary NGAL as a Diagnostic and Prognostic Marker for Acute Kidney Injury in Cirrhosis: A Prospective Study
Allegretti AS, Parada XV, Endres P, Zhao S, Krinsky S, St. Hillien SA, Kalim S, Nigwekar SU, Flood JG, Nixon A, Simonetto DA, Juncos LA, Karakala N, Wadei HM, Regner KR, Belcher JM, Nadim MK, Garcia-Tsao G, Velez JCQ, Parikh SM, Chung RT. Urinary NGAL as a Diagnostic and Prognostic Marker for Acute Kidney Injury in Cirrhosis: A Prospective Study. Clinical And Translational Gastroenterology 2021, 12: e00359. PMID: 33979307, PMCID: PMC8116001, DOI: 10.14309/ctg.0000000000000359.Peer-Reviewed Original ResearchConceptsNeutrophil gelatinase-associated lipocalinUrinary neutrophil gelatinase-associated lipocalinAcute kidney injuryAcute tubular necrosisPrerenal acute kidney injuryHepatorenal syndromeKidney injuryC-statisticManagement of AKITypes of AKIEnd-stage liver disease (MELD) scoreTransplant-free survivalLiver Disease scoreMedian serum creatinineGelatinase-associated lipocalinPrediction of mortalityNet reclassification indexDiscrimination incrementProspective cohortSerum creatinineTubular necrosisProspective studyReclassification indexUnadjusted analysesPrognostic marker
2020
The Role of Telenephrology in the Management of CKD.
Belcher JM. The Role of Telenephrology in the Management of CKD. Kidney360 2020, 1: 1310-1315. PMID: 35372872, PMCID: PMC8815503, DOI: 10.34067/kid.0000802019.Peer-Reviewed Original Research
2018
Quantification of Urinary Protein Biomarkers of Autosomal Dominant Polycystic Kidney Disease by Parallel Reaction Monitoring
Rauniyar N, Yu X, Cantley J, Voss EZ, Belcher J, Colangelo CM, Stone KL, Dahl N, Parikh C, Lam TT, Cantley LG. Quantification of Urinary Protein Biomarkers of Autosomal Dominant Polycystic Kidney Disease by Parallel Reaction Monitoring. Proteomics Clinical Applications 2018, 12: e1700157. PMID: 29573172, PMCID: PMC6736530, DOI: 10.1002/prca.201700157.Peer-Reviewed Original ResearchConceptsAutosomal dominant polycystic kidney diseaseDominant polycystic kidney diseasePolycystic kidney diseaseCyst growthKidney diseaseUrinary proteinNormal controlsEnd-stage renal failureUrine samplesUrinary protein biomarkersLife-long diseasePresence of cystsRespective urine samplesMost patientsRenal failureADPKD patientsEarly diagnosisClinical relevanceUrinary proteomeParallel reaction monitoringPatientsCyst formationDiseaseWater intakePathogenesis
2017
Use of a Targeted Urine Proteome Assay (TUPA) to identify protein biomarkers of delayed recovery after kidney transplant
Williams KR, Colangelo CM, Hou L, Chung L, Belcher JM, Abbott T, Hall IE, Zhao H, Cantley LG, Parikh CR. Use of a Targeted Urine Proteome Assay (TUPA) to identify protein biomarkers of delayed recovery after kidney transplant. Proteomics Clinical Applications 2017, 11 PMID: 28261998, PMCID: PMC5549272, DOI: 10.1002/prca.201600132.Peer-Reviewed Original ResearchConceptsImmediate graft functionKidney transplantGraft functionLong-term graft outcomeMore effective treatmentsProtein biomarkersIGF patientsGraft outcomeIGF levelsPoor outcomeEffective treatmentKidney implantationClinical relevanceBiomarker panelPotential biomarkersUrine proteomeDGFTransplantBiomarkersPatientsOutcomesTreatmentEarly stagesAssaysPrognosisTargeting Access to Kidney Care Via Telehealth: The VA Experience
Crowley ST, Belcher J, Choudhury D, Griffin C, Pichler R, Robey B, Rohatgi R, Mielcarek B. Targeting Access to Kidney Care Via Telehealth: The VA Experience. Advances In Kidney Disease And Health 2017, 24: 22-30. PMID: 28224939, DOI: 10.1053/j.ackd.2016.11.005.Commentaries, Editorials and LettersConceptsVeterans AffairsHealth servicesTelehealth servicesLarge integrated health care systemIntegrated health care systemHealth care venuesSpecialty care servicesHealth care deliveryHealth care systemHealth care valueKidney diseaseSpecialty careVeterans' choiceCare servicesCare deliveryCare venuesCare systemCKDCare valueVeteransHigh rateVA experienceCareVirtual deliveryVA strategy
2016
Urine Interleukin 18 and Lipocalin 2 Are Biomarkers of Acute Tubular Necrosis in Patients With Cirrhosis: A Systematic Review and Meta-analysis
Puthumana J, Ariza X, Belcher JM, Graupera I, Ginès P, Parikh CR. Urine Interleukin 18 and Lipocalin 2 Are Biomarkers of Acute Tubular Necrosis in Patients With Cirrhosis: A Systematic Review and Meta-analysis. Clinical Gastroenterology And Hepatology 2016, 15: 1003-1013.e3. PMID: 28013112, PMCID: PMC5474196, DOI: 10.1016/j.cgh.2016.11.035.Peer-Reviewed Original ResearchConceptsNeutrophil gelatinase-associated lipocalinAcute tubular necrosisUrine levelsUrine biomarkersSystematic reviewKidney impairmentKidney injuryTubular necrosisLipocalin-2Development of ATNAUC valuesEtiology of AKIUrine interleukin-18Acute kidney injuryGelatinase-associated lipocalinShort-term mortalityLogistic mixed-effects modelsHepatorenal syndromeCause mortalityPrerenal azotemiaCommon complicationInterleukin-18Prospective studyPatient outcomesCommon causeA Genome-Wide Association Study to Identify Single-Nucleotide Polymorphisms for Acute Kidney Injury
Zhao B, Lu Q, Cheng Y, Belcher JM, Siew ED, Leaf DE, Body SC, Fox AA, Waikar SS, Collard CD, Thiessen-Philbrook H, Ikizler TA, Ware LB, Edelstein CL, Garg AX, Choi M, Schaub JA, Zhao H, Lifton RP, Parikh CR. A Genome-Wide Association Study to Identify Single-Nucleotide Polymorphisms for Acute Kidney Injury. American Journal Of Respiratory And Critical Care Medicine 2016, 195: 482-490. PMID: 27576016, PMCID: PMC5378420, DOI: 10.1164/rccm.201603-0518oc.Peer-Reviewed Original ResearchMeSH KeywordsAcute Kidney InjuryAdultAgedApolipoprotein L1ApolipoproteinsBiomarkersCardiac Surgical ProceduresCase-Control StudiesCritical IllnessFemaleGenetic Predisposition to DiseaseGenome-Wide Association StudyGenotypeHumansIntensive Care UnitsInterferon Regulatory Factor-2Lipoproteins, HDLMaleMiddle AgedPolymorphism, Single NucleotidePostoperative ComplicationsRisk FactorsStatistics, NonparametricT-Box Domain ProteinsConceptsAcute kidney injuryGenome-wide association studiesSingle nucleotide polymorphismsKidney injuryGenetic lociAssociation studiesExploratory genome-wide association studyAcute kidney injury casesHospital acute kidney injuryCommon genetic variantsIndependent lociGene TBX1Chromosome 4Novel pathwayCritical illnessCardiac surgerySevere complicationsLociPatient populationTherapeutic advancesGenetic variantsGenotype imputationInjury casesExpedite recoveryInjury
2015
Development of a Targeted Urine Proteome Assay for kidney diseases
Cantley LG, Colangelo CM, Stone KL, Chung L, Belcher J, Abbott T, Cantley JL, Williams KR, Parikh CR. Development of a Targeted Urine Proteome Assay for kidney diseases. Proteomics Clinical Applications 2015, 10: 58-74. PMID: 26220717, PMCID: PMC5003777, DOI: 10.1002/prca.201500020.Peer-Reviewed Original ResearchConceptsKidney diseaseUrinary proteinGraft functionImmediate graft functionDelayed graft functionKidney transplant patientsMultiple kidney diseasesTransplant patientsKidney transplantClinical relevancePotential biomarkersUrine proteomeDiseaseAvailable biofluidBiomarkersPatientsProtein biomarkersAssaysSingle assayProteome changesHuman urineQuantifiable proteinsTransplantProteinPeptidesAcute Kidney Injury in Liver Disease: Role of Biomarkers
Belcher JM. Acute Kidney Injury in Liver Disease: Role of Biomarkers. Advances In Kidney Disease And Health 2015, 22: 368-375. PMID: 26311598, DOI: 10.1053/j.ackd.2015.06.009.BooksConceptsAcute kidney injuryEtiology of AKINeutrophil gelatinase-associated lipocalinAcute tubular necrosisGelatinase-associated lipocalinHepatorenal syndromeKidney injuryPrerenal azotemiaTubular necrosisFractional excretionInterleukin-18Urinary neutrophil gelatinase-associated lipocalinProgression of AKIKidney tubular injurySetting of cirrhosisOverall poor outcomeRole of biomarkersStandard diagnostic toolAdvanced cirrhosisAKI etiologyCommon complicationTubular injuryCommon etiologyLiver diseasePoor outcomeCreatinine Change on Vasoconstrictors as Mortality Surrogate in Hepatorenal Syndrome: Systematic Review & Meta-Analysis
Belcher JM, Coca SG, Parikh CR. Creatinine Change on Vasoconstrictors as Mortality Surrogate in Hepatorenal Syndrome: Systematic Review & Meta-Analysis. PLOS ONE 2015, 10: e0135625. PMID: 26295585, PMCID: PMC4546623, DOI: 10.1371/journal.pone.0135625.Peer-Reviewed Original ResearchConceptsDelta creatinineHepatorenal syndromeRelative riskSerum creatininePost-treatment mortalityVasoconstrictor therapyRandomized trialsHRS type 1Completion of treatmentWeb of ScienceRenal functionCreatinine changesOverall mortalitySevere complicationsControl armTreatment periodVasoconstrictor medicationCreatinineElectronic databasesMeta-AnalysisSystematic reviewMortalityType 1PatientsSignificant mortality
2014
Urinary Biomarkers and Progression of AKI in Patients with Cirrhosis
Belcher JM, Garcia-Tsao G, Sanyal AJ, Thiessen-Philbrook H, Peixoto AJ, Perazella MA, Ansari N, Lim J, Coca SG, Parikh CR. Urinary Biomarkers and Progression of AKI in Patients with Cirrhosis. Clinical Journal Of The American Society Of Nephrology 2014, 9: 1857-1867. PMID: 25183658, PMCID: PMC4220770, DOI: 10.2215/cjn.09430913.Peer-Reviewed Original ResearchMeSH KeywordsAcute Kidney InjuryAcute-Phase ProteinsAdultAgedAlbuminuriaBiomarkersDisease ProgressionFatty Acid-Binding ProteinsFemaleHepatitis A Virus Cellular Receptor 1Hospital MortalityHumansInterleukin-18Lipocalin-2LipocalinsLiver CirrhosisMaleMembrane GlycoproteinsMiddle AgedPredictive Value of TestsProspective StudiesProto-Oncogene ProteinsReceptors, VirusSodiumConceptsProgression of AKIAKI progressionIL-18Urinary biomarkersHospital mortalityKIM-1End-stage liver disease (MELD) scoreL-FABPStage liver disease scoreNeutrophil gelatinase-associated lipocalinAKI Network criteriaLiver Disease scoreProspective cohort studyGelatinase-associated lipocalinNet reclassification indexUnited States medical centersKey clinical variablesRobust clinical modelKidney injuryCohort studySevere complicationsLiver cirrhosisRisk stratificationClinical variablesMarker levels